Sentynl Therapeutics

Focus: Sentynl Therapeutics is a public biotechnology company headquartered in Solana Beach, CA, focused on small-molecule therapies across neurology, oncology, and rare diseases. The company operates a portfolio of marketed and pipeline programs targeting high-unmet-need indications.

Neurology Oncology Rare Diseases Unknown

Profile data last refreshed 9h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Sentynl Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Sentynl Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

3 in 5yr

NULIBRY

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

NULIBRY

Mortality reduction in molybdenum cofactor deficiency (MoCD) Type A

LOE Approaching

Help build intelligence for Sentynl Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio includes rare-disease franchises (NULIBRY for molybdenum cofactor deficiency, ZYCUBO for Menkes disease) with limited competitive landscapes and strong patient advocacy.
Public company status provides equity upside and established operational infrastructure absent in pre-revenue biotech.
Marketed products (NULIBRY, ZOKINVY, ABSTRAL) generate revenue to fund R&D without reliance on continuous fundraising cycles.

Watch Out For

Currently zero open positions listed; hiring appears paused or inactive, limiting near-term employment opportunities.
Patent cliffs approaching for two key products (NULIBRY by 2029-04, ZOKINVY by 2029-07) create revenue cliff risk and potential restructuring pressure.
Minimal disclosed pipeline activity (only 2 total trials across all phases) suggests limited clinical catalysts and innovation momentum.

Generated by Claude from Sentynl Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Rare-disease franchise addressing a fatal genetic condition; substrate-replacement mechanism with limited competitive alternatives but patent expiry in ~5 years.

ZYCUBO

Menkes Disease

Launch4.4yr

Recently launched rare-disease therapy targeting copper-metabolism disorder; earliest LOE among portfolio, providing extended revenue runway.

ABSTRAL

Breakthrough cancer pain

LOE Approaching

Established opioid analgesic with mature market; patent cliff timing uncertain, but likely faced with generic competition.

ZOKINVY

Progeria (Hutchinson-Gilford Progeria Syndrome)

Peak2.9yr

Peak-stage farnesyltransferase inhibitor for ultra-rare genetic disease; limited patient population but strong clinical differentiation; patent cliff 2029-07.